^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ORB-011

    i
    Other names: ORB-011
    Associations

    News

    Trials
    Company:
    Orionis
    Drug class:
    Immunomodulator, Dendritic cell activator
    Related drugs:
    Associations

    News

    Trials
    3ms
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, Orionis Biosciences Inc | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    ORB-011
    7ms
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, Orionis Biosciences Inc | Recruiting --> Active, not recruiting | N=36 --> 55
    Enrollment closed • Enrollment change
    |
    ORB-011
    9ms
    ORB-011 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Orionis Biosciences Inc | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    ORB-011
    over2years
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Orionis Biosciences Inc
    New P1 trial • Metastases
    |
    ORB-011